Logo Image
Commentary|Podcasts|August 11, 2026

Breaking the Efficacy Ceiling in IBD and Beyond

AbbVie’s head of immunology clinical development, Kori Wallace, MD, PhD, discusses how combination therapies, translational science, and emerging immune-reset approaches could usher in a new era of treatment for inflammatory bowel disease and other autoimmune conditions.

Despite significant advances in treating inflammatory bowel disease (IBD) and other autoimmune conditions, many patients still fail to achieve lasting remission. In this video episode of the Applied Clinical Trials podcast, Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, examines the biological complexity behind this persistent “efficacy ceiling” and the strategies being pursued to move beyond incremental gains.

Wallace explores the shift toward more stringent, tissue-based treatment targets; the potential of combining complementary mechanisms; and the ongoing search for biomarkers that can make precision medicine practical in immunology. She also dives into the promise of B-cell depletion and in vivo CAR-T approaches designed to reset the immune system, potentially opening a path toward deep, durable, drug-free remission.

Other conversation highlights include:

  • The effectiveness plateau: Why symptom improvement alone is no longer an adequate treatment goal in IBD clinical trials and how endoscopic and histologic measures are raising expectations.
  • Precision medicine's unfinished business: Immunology still lags behind oncology in biomarker-driven treatment selection, hampering the predictive accuracy the field needs to make personalized treatment truly meaningful for clinicians.
  • Are new advances turning the tide?: What translational science, spatial transcriptomics, AI, and machine learning may contribute to identifying meaningful predictive biomarkers.
  • A "third wave" of in vivo CAR T therapy: How AbbVie and other developers aim to reset the immune system without the burdens of ex vivo cell therapy.

Click below to listen to the audio version and subscribe to the Applied Clinical Trials Podcast:

Related to this article

View more
Where AI Leads in Trial Design—and Where Humans Still Need To
Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
Read more
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
Read more
© putilov_denis - © putilov_denis - stock.adobe.com
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.
Read more